Moderna shares surge as melanoma vaccine with Merck succeeds in large trial

Moderna’s stock price exploded in premarket trading on Wednesday, jumping 60% following the news that its experimental skin cancer vaccine hit its targets in a large-scale clinical trial. The pharmaceutical giant collaborated with Merck to combine its mRNA technology with the established immunotherapy drug Keytruda.

The latest interim data for the treatment, known as Intismeran, confirms it met key goals for preventing cancer recurrence. Additionally, the study showed the therapy was successful in stopping the disease from spreading to other organs in the body.

Customized Care for Deadly Tumors

Unlike traditional mass-produced vaccines, this mRNA treatment is tailored to the individual. Scientists analyze the specific mutations found within a patient’s own tumor to create a made-to-order shot that helps the immune system identify and destroy cancer cells.

The phase three trial involved 1,137 participants suffering from high-risk melanoma who had previously undergone surgery. Some volunteers received a combination of the personalized vaccine and Keytruda for one year, while others received only the immunotherapy drug.

A Financial and Medical Pivot

This success marks a significant shift for Moderna as it moves beyond its COVID-19 origins. The company is aggressively diversifying its pipeline with approved flu shots and experimental treatments for Lyme disease and norovirus.

Market analysts at Barclays have already projected that this melanoma therapy could bring in $3 billion by 2035. While the stock surge was the headline on Wall Street, the companies noted that no new safety concerns were identified during this phase of the study.

The Road to Regulation

Previous data from mid-stage trials suggested the treatment could slash the risk of death or cancer recurrence by 49% over a five-year period. These impressive figures have made the vaccine a high-stakes catalyst for the firm's future growth.

Moderna and Merck plan to present the full findings at an upcoming medical conference and will begin sharing the data with global health regulators. Melanoma remains the most lethal version of skin cancer, affecting over 1.5 million people in the U.S. alone.